Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)

Osteoporosis Clinical Trial

Official title:

Improving Management of Patients at High Risk for Osteoporotic Fractures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00139438
• Other study ID #: 0000-038
• Secondary ID: 0382005_049
• Status: Completed
• Phase: N/A
• First received: August 29, 2005
• Last updated: October 9, 2015
• Start date: September 2004
• Est. completion date: June 2005

Study information

• Verified date: October 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4266
• Est. completion date: June 2005
• Est. primary completion date: June 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

• Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporotic Fractures

Intervention

Behavioral:
• Disease Management Assessment

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.
Secondary	BMD testing, osteoporosis medication prescriptions, fracture